Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Invokana

- PMLiVE

Biosimilar Remicade reaches market in Japan and India

Nippon Kayaku’s version of arthritis drug was approved in July

- PMLiVE

Olysio drives J&J pharma sales

But hepatitis C drug set to face serious competition from Gilead Sciences

- PMLiVE

Pharma spent $342m on journal advertising in first half of 2014

J&J led spending and Invokana was most advertised brand

- PMLiVE

FDA approves J&J’s diabetes combo

Invokamet combines Invokana and metformin to help reduce blood sugar

- PMLiVE

NICE backs Janssen’s once-daily diabetes drug

Invokana is the tenth treatment recommended in England and Wales to lower blood sugar levels

- PMLiVE

J&J brings its Care4today mobile adherence programme to the UK

Launches the mobile app in its first market outside the US

- PMLiVE

Invokana set for NICE recommendation

Janssen drug will provide another treatment option in diabetes

EU flag

J&J wins EU approval for diabetes combo

Vokanamet combines Invokana and metformin

- PMLiVE

J&J’s Care4Today brand joins Twitter

Firm's Janssen Healthcare Innovation unit also makes its debut on the social network

National Institute for Health and Care Excellence NICE logo

Janssen launches diabetes drug Invokana in UK

Launch coincides with draft NICE recommendation for the SGLT2 inhibitor

- PMLiVE

Janssen Invokana combination recommended for European approval

Drug adds metformin to the firm's new SGLT2 inhibitor

- PMLiVE

J&J sells diagnostics unit to private equity firm

Ortho-Clinical Diagnostics acquired by the Carlyle Group

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links